Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): A phase II study in elderly or poor performance status patients

Lung Cancer

Volumn 53, Issue 3, 2006, Pages 355-360

  Santo, Antonio ^a,e   Genestreti, Giovenzio ^a,e   Terzi, Alberto ^b,e   Azzoni, Paolo ^c   Sava, Teodoro ^a   Manno, Pietro ^a   Molino, Annamaria ^a   Pattaro, Cristian ^a   Micciolo, Rocco ^d   Cetto, Gian Luigi ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Azienda Ospedaliera   (Italy)

^c Day Hospital of Medical Oncology   (Italy)

^d UNIVERSITY OF TRENTO   (Italy)

^e Gruppo Interdisciplinare Veronese di Oncologia Polmonare (GIVOP)   (Italy)

Author keywords

Advanced NSCLC; Gemcitabine; Non platinum based chemotherapy; Vindesine

Indexed keywords

GEMCITABINE; METOCLOPRAMIDE; VINDESINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG ACTIVITY; DRUG FEVER; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAIR LOSS; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PAIN; TIME FACTORS; TREATMENT OUTCOME; VINDESINE;

EID: 33747072054     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.05.013     Document Type: Article

References (31)

1. Fry W.A., Menck H.R., and Winchester D.P. The National Cancer Data Base report on lung cancer. Cancer 77 (1996) 1947-1955
2. Non Small Cell Lung Cancer Cooperative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using update data on individual patients from 52 randomized clinical trials. Br Med J 311 (1995) 899-909
3. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Under representation of patients of 65 years of age or older in cancer treatment trials. N Engl J Med 341 (1999) 2061-2067
4. Janssen-Heijnen M.L. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population based study. Lung Cancer 21 2 (1998) 105-113
5. Extermann M., Overcash J., Lyman G.H., Parr J., and Balducci L. Comorbidity and functional status are independent in older patients. J Clin Oncol 16 (1998) 582-587
6. Oshita F., Kurata T., Kasai T., Fakuda M., Yamamoto N., Ohe Y., et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86 (1995) 1198-1202
7. Gatzemeier U., Shepherd F.A., Le Chevalier T., Weynants P., Cottier B., Groen H.J., et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter extended phase II study. Eur J Cancer 32 (1996) 243-248
8. Shepherd F.A., Abratt R.P., Anderson H., Gatzemeier U., Anglin G., and Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 24 Suppl 7 (1997) 50-55
9. Abratt R.P., Bezwoda W.R., Falkson G., Goedhals L., Hacking D., and Rugg T.A. Efficacy and safety profile of gemcitabine in non small cell lung cancer: a phase II study. J Clin Oncol 12 (1994) 1535-1540
10. Abratt R.P., Hacking D.J., Goedhals L., and Bezwoda W.R. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15 (1997) 744-749
11. Crino L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 15 (1997) 297-303
12. Sorensen J.B., and Hansen H.H. Is there a role for vindesine in the treatment of non-small cell lung cancer. Invest New Drugs 11 (1993) 103-133
13. Kris M.G., Gralla R.J., Kalman L.A., Kelsen D.P., Casper E.S., Burke M.T., et al. Randomized trial comparing vindesine plus cisplatin with vinblastine and cisplatin in patients with non small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 69 4 (1985) 387-395
14. Sorensen J.B., Bergman B., Nielsen A.L., Krarup M., Dombernowsky P., and Hansen H.H. Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small cell lung cancer. Br J Cancer 79 (1999) 875-881
15. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979.
16. Burris III H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 6 (1997) 2403-2413
17. Stinchcombe T.E., and Socinski M.A. Drug development in patients with advanced non small cell lung cancer and poor performance status. Semin Oncol 31 6 Suppl 11 (2004) 21-26
18. Gatzemeier U., Shepherd F.A., Le Chevalier T., Weynants P., Cottier B., Groen H.J., et al. Activity of gemcitabine on patients with non-small cell lung cancer: a multicenter extended phase II study. Eur J Cancer 32 (1996) 243-248
19. Gridelli C., Perrone F., Gallo C., De Marinis F., Ianniello G., Cigolari S., et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer 33 (1997) 392-397
20. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
21. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., and Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen on advanced non-small cell lung cancer: a meta-analysis. JAMA 292 4 (2004) 470-484
22. Gridelli C., Frontini L., Perrone F., Gallo C., Gulisano M., Cigolari S., et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br J Cancer 83 6 (2000) 707-714
23. Beretta G.D., Michetti G., Belometti M.O., Gritti G., Quadri A., Poletti P., et al. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 83 5 (2000) 573-576
24. Lilenbaum R., Cano R., Schwartz M., Siegel L., Lutzky J., Lewis M., et al. Gemcitabine and vinorelbine in advanced non-small cell lung carcinoma. Cancer 88 3 (2000) 557-562
25. Bajetta E., Chiara Stani S., De Candis D., Bidoli P., Mariani L., Zilembo N., et al. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced non-small cell lung carcinoma: a phase II trial. Cancer 89 4 (2000) 763-768
26. Palmeri S., Leonardi V., Gebbia V., De Bella M.T., Ferrau F., Faillu G., et al. Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicenter phase II trial. Lung Cancer 34 (2002) 115-123
27. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 5 (2003) 362-372
28. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18 13 (2000) 2536-2539
29. Abratt RP, Szczesna A, Mattson K, Wernli M, Reiterer P, Hui R, et al. Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patients benefit analysis. Proc Am Clin Oncol; 2004.
30. Kanzawa F., and Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 24 Suppl 7 (1997) 7-16
31. Furuse K., Fukuoka M., Kuba M., Yamori S., Nakai Y., Negoro S., et al. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small cell lung cancer (NSCLC). Ann Oncol 7 (1996) 815-820